Pfizer and Biohaven's Vydura receive marketing authorisation from EC
Pfizer and Biohaven Pharmaceutical have announced receipt of marketing authorisation from the European Commission (EC) for Vydura (rimegepant).
📰 Human Use News
Page 144 - Human Use News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Human Use. Real-time updates on events, politics, business and more.
BioMarin Announces Record Revenues in First Quarter 2022
Press release content from PR Newswire. The AP news staff was not involved in its creation.
United States Czech Republic Saudi Arabia United Arab Emirates Debra Charlesworth Biomarin Aldurazyme
Source: apnews.com
Seagen Reports First Quarter 2022 Financial Results
28.04.2022 - Seagen Inc. (Nasdaq:SGEN) reported financial results today for the first quarter ended March 31, 2022. The Company also highlighted PADCEV (enfortumab vedotin-ejfv), TUKYSA (tucatinib), ADCETRIS (brentuximab vedotin) and TIVDAK (tisotumab ...
Source: wallstreet-online.de
Pfizer Inc.: Pfizer and Biohaven's VYDURA (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing authorization for VYDURA (rimegepant), a
Source: finanznachrichten.de
Valneva's Covid-19 vaccine hits another bump with EMA request for further data
The latest request marks the third time the French company was questioned about its Covid-19 vaccine by the European agency.
Source: pharmaceutical-technology.com
BioMarin Announces Record Revenues in First Quarter 2022
BioMarin Reports Record First Quarter Total Revenues of $519 Million Driven by a $20 Million VOXZOGO Contribution; Total Revenues Grew 11% Year-ov...
United States Czech Republic Saudi Arabia United Arab Emirates Debra Charlesworth Biomarin Aldurazyme
Source: businessinsider.com
Advancing therapy – European innovation in a time of post-COVID-19
Good afternoon, health colleagues, and welcome to the European Alliance for Personalised Medicine (EAPM) update – it has certainly been busy for EAPM of late, with Advanced Therapy Medicinal Products (ATMPs), writes EAPM Executive Director Dr. Denis Horgan. Advanced Therapy Medicinal Products (ATMP) EAPM has recently published an article on Advanced Therapy Medicinal Products (ATMPs) – this […]
Source: eureporter.co
Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer · BioBuzz
Incyte (Nasdaq:INCY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency’s (EMA) has issued a positive opinion that recommends granting marketing authorization for capmatinib (Tabrecta®) as a monotherapy for the treatment of adults with advanced non-small cell lung cancer (NSCLC) harboring alterations leading to mesenchymalepithelial-transition factor gene (MET) exon 14 (METex14) skipping who require systemic therapy following prior treatm...
United States Juergen Wolf Peter Langmuir Le Mouhaer Capmatinib Tabrecta American Society Of Clinical Oncology
Source: biobuzz.io
Virus: US judge to block plan to lift border curbs for migrants
Drugmaker Valneva said that the EMA asked for more data on its COVID-19 jab while Cuba recorded 237 daily cases, the lowest daily count of the year.
Source: chinadailyhk.com
Idorsia Pharmaceuticals Ltd: Idorsia announces financial results for the first quarter 2022 - first product launched, second in the starting blocks
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - April 26, 2022 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2022. Business highlights PIVLAZ
United States Switzerland General Andrewc Weiss Neurocrine Biosciences Satoshi Tanaka Jennifer Aniston
Source: finanznachrichten.de